IBIO on XNAS, Health Care, iBio, Inc., job postings
Measures activity, not value. Not investment advice.
Revenue rose 115% to $1.1M but a delisting notice arrived as cash burn reached $27.6M over 12 months.
BadShort interest rose 8.1% in two weeks to 5.7% of shares
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
iBio Inc is a clinical-stage biotechnology company using Artificial Intelligence (AI) for the development of hard-to-drug precision antibodies for obesity, cardiometabolic, and cardiopulmonary diseases. Its product candidate pipeline includes IBIO-610, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody program targeting myostatin, growth differentiation factor 11 (GDF11), and Activin A; IBIO-600; Amylin Antibody; and Target 4, in different stages of development, being developed as potential therapies for obesity and cardiometabolic disease. The company operates as one reportable segment, which is that of a biotechnology company leveraging AI and ML for the development of hard-to-drug precision antibodies.
expected around 9 Feb 2027 (an estimate: a year ago it reported on 10 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $1.1M, net loss $7.6M.
31 Dec 2021RevenueNet incomeNet losstallest bar $33.6M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$1.1M
-$7.6M
30 Jun 2026
$0
-$10.6M
31 Mar 2026
$0
-$7.7M
31 Dec 2025
$0
-$9.0M
30 Sep 2025
$100K
-$5.7M
30 Jun 2025
$200K
-$5.2M
31 Mar 2025
$0
-$4.9M
31 Dec 2024
$200K
-$4.4M
30 Sep 2024
$0
-$4.0M
30 Jun 2024
$175K
-$7.8M
31 Mar 2024
–
-$3.2M
31 Dec 2023
–
-$8.2M
30 Sep 2023
$50K
-$5.7M
30 Jun 2023
–
-$6.0M
31 Mar 2023
$0
-$7.3M
31 Dec 2022
$0
-$33.6M
30 Sep 2022
$0
-$18.1M
30 Jun 2022
$61K
-$17.1M
31 Mar 2022
$1.9M
-$12.4M
31 Dec 2021
$168K
-$11.9M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$1.1M
$500K
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
+115%
+11%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
-$34.9M
-$20.1M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
–
–
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
–
–
73.2%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
–
–
-25.0%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
–
–
-18.2%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
-51.8%
-58.8%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
-$27.6M
-$17.3M
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$76.7M
$49.6M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
–
$706K
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
–
-$48.9M
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
–
0.0
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$1.12
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
loss
19.3
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
52.4
5.0
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
–
5.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
0.72
2.0
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Insider Buy/Sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
–
No data for this company
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
+5.4%
59 13F filers vs 56
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
53%
37.5M shares held by 13F filers (30 Sep 2026) of 70.5M outstanding (10 Nov 2026)
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
5.7%
4.0M shares sold short (30 Oct 2026) of 70.5M outstanding (10 Nov 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
7.2
4.0M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
+8.1%
3.7M shares sold short in the report before, 4.0M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
7.4%
7.4% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 41%
Open jobs iJob postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.
2
Tracked since 21 Nov 2026
Open jobs change iHow the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.
–
Tracking started 21 Nov 2026; the change shows after 30 days.
Employees iTotal staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.
–
No headcount in its annual reports in our data.
Visa hiring (foreign workers) iApplications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.
–
No data for this company
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
–
No data for this company
Capital spending iMoney spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.
–
No data for this company
Federal contracts iMoney the US government committed to the company in contracts and grants over the last 12 months.
–
No data for this company
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
–
No data for this company
Layoff notices iWorkers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).
–
No data for this company
News (7d) iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
11
11 articles in the last 7 days; its usual week has 0.5 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
–
11 articles in the last 7 days; its usual week has 0.5: fewer than one, so there is nothing to compare with.
Price $0.80 on 20 Nov 2026, -20% over 12 months (12-month range $0.71 to $3.07)
Sharp change
8-K and other filings
Lobbying filing
Insider net buying (open market). Insiders bought a net $98K in the last 12 months (the 12 months before: $655K).Revenue per quarter. Revenue $1.1M in the latest quarter, +975% on a year earlier.Capital spending per quarter. Capital spending $102K in the latest quarter, +219% on a year earlier.Institutional holders (13F filers). 59 13F filers reported holding it in the latest 13F quarter, +84% on a year earlier.Lobbying spend. Lobbying spend: $0 published in the last 12 months.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, federal obligations, workers in warn layoff notices.
Quarter ended 31 Dec 2021: $168K, -76% on a year earlier; public on 15 Feb 2022
Quarter ended 31 Mar 2022: $1.9M, +154% on a year earlier; public on 13 May 2022
Quarter ended 30 Jun 2022: $61K, -88% on a year earlier; public on 12 Oct 2022
Quarter ended 30 Sep 2022: $0, -100% on a year earlier; public on 15 Nov 2022
Quarter ended 31 Dec 2022: $0, -100% on a year earlier; public on 15 Feb 2023
Quarter ended 31 Mar 2023: $0, -100% on a year earlier; public on 16 May 2023
Quarter ended 30 Sep 2023: $50K; public on 15 Nov 2023
Quarter ended 30 Jun 2024: $175K; public on 21 Sep 2024
Quarter ended 30 Sep 2024: $0, -100% on a year earlier; public on 13 Nov 2024
Quarter ended 31 Dec 2024: $200K; public on 11 Feb 2025
Quarter ended 31 Mar 2025: $0; public on 3 May 2025
Quarter ended 30 Jun 2025: $200K, +14% on a year earlier; public on 6 Sep 2025
Quarter ended 30 Sep 2025: $100K; public on 13 Nov 2025
Quarter ended 31 Dec 2025: $0, -100% on a year earlier; public on 11 Feb 2026
Quarter ended 31 Mar 2026: $0; public on 13 May 2026
Quarter ended 30 Jun 2026: $0, -100% on a year earlier; public on 29 Aug 2026
Quarter ended 30 Sep 2026: $1.1M, +975% on a year earlier; public on 11 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $2.1M, +115% on a year earlier; public on 15 Feb 2022
Quarter ended 31 Mar 2022: $644K, -35% on a year earlier; public on 13 May 2022
Quarter ended 30 Jun 2022: $3.4M, +36% on a year earlier; public on 12 Oct 2022
Quarter ended 30 Sep 2022: $2.5M, +121% on a year earlier; public on 15 Nov 2022
Quarter ended 31 Dec 2022: $3.0M, +38% on a year earlier; public on 15 Feb 2023
Quarter ended 30 Jun 2023: $506K, -85% on a year earlier; public on 28 Sep 2023
Quarter ended 31 Mar 2024: $0; public on 3 May 2025
Quarter ended 30 Jun 2024: $210K, -58% on a year earlier; public on 21 Sep 2024
Quarter ended 30 Sep 2024: $0; public on 13 Nov 2025
Quarter ended 31 Dec 2024: $1K; public on 11 Feb 2025
Quarter ended 30 Jun 2025: $1K, -100% on a year earlier; public on 6 Sep 2025
Quarter ended 30 Sep 2025: $32K; public on 13 Nov 2025
Quarter ended 31 Dec 2025: $516K, +51500% on a year earlier; public on 11 Feb 2026
Quarter ended 31 Mar 2026: $11K; public on 13 May 2026
Quarter ended 30 Jun 2026: $19K, +1800% on a year earlier; public on 29 Aug 2026
Quarter ended 30 Sep 2026: $102K, +219% on a year earlier; public on 11 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 74; public on 14 Feb 2022
31 Mar 2022 report: 68; public on 16 May 2022
30 Jun 2022 report: 53; public on 15 Aug 2022
30 Sep 2022 report: 41; public on 14 Nov 2022
31 Dec 2022 report: 34; public on 14 Feb 2023
31 Mar 2023 report: 28; public on 15 May 2023
30 Jun 2023 report: 25; public on 14 Aug 2023
30 Sep 2023 report: 25; public on 14 Nov 2023
31 Dec 2023 report: 19; public on 14 Feb 2024
31 Mar 2024 report: 25; public on 15 May 2024
30 Jun 2024 report: 28; public on 14 Aug 2024
30 Sep 2024 report: 31; public on 14 Nov 2024
31 Dec 2024 report: 30; public on 14 Feb 2025
31 Mar 2025 report: 34; public on 15 May 2025
30 Jun 2025 report: 28; public on 14 Aug 2025
30 Sep 2025 report: 32; public on 14 Nov 2025
31 Dec 2025 report: 48; public on 17 Feb 2026
31 Mar 2026 report: 49; public on 15 May 2026
30 Jun 2026 report: 56; public on 14 Aug 2026
30 Sep 2026 report: 59; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Jan 2022: $30K published
Quarter from 1 Apr 2022: $30K published
Quarter from 1 Jul 2022: $60K published
What is unusual now
Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is insider open-market buying (USD, Form 4) at $23K (27 Mar 2026), higher than 73% of its own history.
In 12 months: 3 director or officer changes, 2 major agreements, 1 private placement, 1 agreement ended. Results releases and routine reports are left out.
Filed
What happened
Source
20 Nov 2026
Nasdaq notice: bid price below $1.00 for 30 consecutive business days; has until May 18, 2027 to regain compliance
Reported lobbying spend: $30K in Q3 2022, $30K in Q2 2022. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.
Date
Change
Lobbying firm
Issue
Source
30 Sep 2022
Ended
The Petrizzo Group, Inc.for Ibio, Inc.
Advance iBio as the leader in plant-made pharmaceutical manufacturing and collaboration between the U.S. Government for research and development of domestic advanced vaccine manufacturing platforms. COVID-19 pandemic preparedness.; Funding for advanced manufacturing technologies that utilize plantsHealth issues, MED, Budget
Specific focus on plant-made pharmaceutical manufacturing of vaccines, and therapies, and funding for research and direct manufacturing with the U.S. Government or other commercial partners.Health issues, MED
Two or more unrelated kinds of records unusual within 30 days
17 Feb 2026confirmed
Confirmed across sources Institutional holdings and Short interest and volume
iBio(IBIO): had 3.9M shares sold short in the 15 Jan 2026 report, 16× the same report last year, while it saw 25 13F filers open a new position in the quarter ended 31 Dec 2025, against none in the same quarter last year. Two unrelated kinds of activity within 28 days.
Short interest and volume: Short interest spike, became public on 28 Jan 2026
Institutional holdings: Many funds opening a new position, became public on 17 Feb 2026
Short interest and volume: Short interest spike, became public on 11 Feb 2026
Short interest and volume: Short interest spike, became public on 26 Feb 2026
The 15 Jan 2026 report against the 24 reports before it.
this reportearliernormal: 903KSee the evidence (4 changes)
Short interest and volume: Short interest spike became public on 28 Jan 2026
iBio had 3.9M shares sold short in the 15 Jan 2026 report, 16× the same report last year.
This period
3.9M (the 15 Jan 2026 report)
Normal report (median of 24 earlier)
903K
Typical spread (median absolute deviation)
433K
How far from its usual level
+4.7
Same report last year
242K
History used
2,939 days
the 15 Jan 2026 report24 earlier reportsnormal: 903K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Institutional holdings: Many funds opening a new position became public on 17 Feb 2026
iBio saw 25 13F filers open a new position in the quarter ended 31 Dec 2025, against none in the same quarter last year.
This period
25 (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
5.5
Typical spread (median absolute deviation)
1.5
How far from its usual level
+6.5
Same quarter last year
0
History used
4,475 days
the quarter ended 31 Dec 20258 earlier quartersnormal: 5.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Short interest and volume: Short interest spike became public on 11 Feb 2026
iBio had 3.9M shares sold short in the 30 Jan 2026 report, 18× the same report last year.
This period
3.9M (the 30 Jan 2026 report)
Normal report (median of 24 earlier)
915K
Typical spread (median absolute deviation)
444K
How far from its usual level
+4.5
Same report last year
214K
History used
2,954 days
the 30 Jan 2026 report24 earlier reportsnormal: 915K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 26 Feb 2026
iBio had 4.2M shares sold short in the 13 Feb 2026 report, 9.2× the same report last year.
This period
4.2M (the 13 Feb 2026 report)
Normal report (median of 24 earlier)
1.0M
Typical spread (median absolute deviation)
557K
How far from its usual level
+3.8
Same report last year
454K
History used
2,968 days
the 13 Feb 2026 report24 earlier reportsnormal: 1.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
19 May 2020confirmed
Confirmed across sources Lobbying and Short interest and volume
iBio(IBIO): had 4.0M shares sold short in the 30 Apr 2020 report, 11× the same report last year, while it registered for federal lobbying for the first time in our data (Steptoe Llp). Two unrelated kinds of activity within 35 days.
Short interest and volume: Short interest spike, became public on 25 Apr 2020
Short interest and volume: Short interest spike, became public on 12 May 2020
Lobbying: First lobbying registration, became public on 19 May 2020
Short interest and volume: Short interest spike, became public on 28 May 2020
The 30 Apr 2020 report against the 24 reports before it.
this reportearliernormal: 342KSee the evidence (4 changes)
Short interest and volume: Short interest spike became public on 25 Apr 2020
iBio had 2.5M shares sold short in the 15 Apr 2020 report, 6.8× the same report last year.
This period
2.5M (the 15 Apr 2020 report)
Normal report (median of 24 earlier)
342K
Typical spread (median absolute deviation)
223K
How far from its usual level
+6.5
Same report last year
365K
History used
838 days
the 15 Apr 2020 report24 earlier reportsnormal: 342K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 12 May 2020
iBio had 4.0M shares sold short in the 30 Apr 2020 report, 11× the same report last year.
This period
4.0M (the 30 Apr 2020 report)
Normal report (median of 24 earlier)
342K
Typical spread (median absolute deviation)
257K
How far from its usual level
+9.6
Same report last year
361K
History used
853 days
the 30 Apr 2020 report24 earlier reportsnormal: 342K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
"First" means first in our data: it fires only when the source's history began at least 365 days earlier.
Short interest and volume: Short interest spike became public on 28 May 2020
iBio had 2.8M shares sold short in the 15 May 2020 report, 9.4× the same report last year.
This period
2.8M (the 15 May 2020 report)
Normal report (median of 24 earlier)
343K
Typical spread (median absolute deviation)
274K
How far from its usual level
+6.1
Same report last year
303K
History used
868 days
the 15 May 2020 report24 earlier reportsnormal: 343K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
had 4.2M shares sold short in the 13 Feb 2026 report, 9.2× the same report last year.
Same report last year: 454K; its normal report is 1.0M.
See the evidence
This period
4.2M (the 13 Feb 2026 report)
Normal report (median of 24 earlier)
1.0M
Typical spread (median absolute deviation)
557K
How far from its usual level
+3.8
Same report last year
454K
History used
2,968 days
the 13 Feb 2026 report24 earlier reportsnormal: 1.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 3.9M shares sold short in the 15 Jan 2026 report, 16× the same report last year, while it saw 25 13F filers open a new position in the quarter ended 31 Dec 2025, against none in the same quarter last year. Two unrelated kinds of activity within 28 days.
See the evidence (4 changes)
Short interest and volume: Short interest spike became public on 28 Jan 2026
iBio had 3.9M shares sold short in the 15 Jan 2026 report, 16× the same report last year.
This period
3.9M (the 15 Jan 2026 report)
Normal report (median of 24 earlier)
903K
Typical spread (median absolute deviation)
433K
How far from its usual level
+4.7
Same report last year
242K
History used
2,939 days
the 15 Jan 2026 report24 earlier reportsnormal: 903K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Institutional holdings: Many funds opening a new position became public on 17 Feb 2026
iBio saw 25 13F filers open a new position in the quarter ended 31 Dec 2025, against none in the same quarter last year.
This period
25 (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
5.5
Typical spread (median absolute deviation)
1.5
How far from its usual level
+6.5
Same quarter last year
0
History used
4,475 days
the quarter ended 31 Dec 20258 earlier quartersnormal: 5.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Short interest and volume: Short interest spike became public on 11 Feb 2026
iBio had 3.9M shares sold short in the 30 Jan 2026 report, 18× the same report last year.
This period
3.9M (the 30 Jan 2026 report)
Normal report (median of 24 earlier)
915K
Typical spread (median absolute deviation)
444K
How far from its usual level
+4.5
Same report last year
214K
History used
2,954 days
the 30 Jan 2026 report24 earlier reportsnormal: 915K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 26 Feb 2026
iBio had 4.2M shares sold short in the 13 Feb 2026 report, 9.2× the same report last year.
This period
4.2M (the 13 Feb 2026 report)
Normal report (median of 24 earlier)
1.0M
Typical spread (median absolute deviation)
557K
How far from its usual level
+3.8
Same report last year
454K
History used
2,968 days
the 13 Feb 2026 report24 earlier reportsnormal: 1.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
17 Feb 2026Institutional holdings change
saw 25 13F filers open a new position in the quarter ended 31 Dec 2025, against none in the same quarter last year.
See the evidence
This period
25 (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
5.5
Typical spread (median absolute deviation)
1.5
How far from its usual level
+6.5
Same quarter last year
0
History used
4,475 days
the quarter ended 31 Dec 20258 earlier quartersnormal: 5.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
had 3.9M shares sold short in the 30 Jan 2026 report, 18× the same report last year.
Same report last year: 214K; its normal report is 915K.
See the evidence
This period
3.9M (the 30 Jan 2026 report)
Normal report (median of 24 earlier)
915K
Typical spread (median absolute deviation)
444K
How far from its usual level
+4.5
Same report last year
214K
History used
2,954 days
the 30 Jan 2026 report24 earlier reportsnormal: 915K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 3.9M shares sold short in the 15 Jan 2026 report, 16× the same report last year.
Same report last year: 242K; its normal report is 903K.
See the evidence
This period
3.9M (the 15 Jan 2026 report)
Normal report (median of 24 earlier)
903K
Typical spread (median absolute deviation)
433K
How far from its usual level
+4.7
Same report last year
242K
History used
2,939 days
the 15 Jan 2026 report24 earlier reportsnormal: 903K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 3.8M shares sold short in the 31 Dec 2025 report, 20× the same report last year.
Same report last year: 190K; its normal report is 877K.
See the evidence
This period
3.8M (the 31 Dec 2025 report)
Normal report (median of 24 earlier)
877K
Typical spread (median absolute deviation)
406K
How far from its usual level
+4.8
Same report last year
190K
History used
2,924 days
the 31 Dec 2025 report24 earlier reportsnormal: 877K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 3.9M shares sold short in the 15 Dec 2025 report, 15× the same report last year.
Same report last year: 256K; its normal report is 839K.
See the evidence
This period
3.9M (the 15 Dec 2025 report)
Normal report (median of 24 earlier)
839K
Typical spread (median absolute deviation)
369K
How far from its usual level
+5.6
Same report last year
256K
History used
2,908 days
the 15 Dec 2025 report24 earlier reportsnormal: 839K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.5M shares sold short in the 31 Oct 2025 report, 9.5× the same report last year.
Same report last year: 260K; its normal report is 594K.
See the evidence
This period
2.5M (the 31 Oct 2025 report)
Normal report (median of 24 earlier)
594K
Typical spread (median absolute deviation)
333K
How far from its usual level
+3.8
Same report last year
260K
History used
2,863 days
the 31 Oct 2025 report24 earlier reportsnormal: 594K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.1M shares sold short in the 29 Aug 2025 report, 24× the same report last year.
Same report last year: 90K; its normal report is 461K.
See the evidence
This period
2.1M (the 29 Aug 2025 report)
Normal report (median of 24 earlier)
461K
Typical spread (median absolute deviation)
265K
How far from its usual level
+4.3
Same report last year
90K
History used
2,800 days
the 29 Aug 2025 report24 earlier reportsnormal: 461K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.7M shares sold short in the 30 Apr 2025 report, 13× the same report last year.
Same report last year: 135K; its normal report is 196K.
See the evidence
This period
1.7M (the 30 Apr 2025 report)
Normal report (median of 24 earlier)
196K
Typical spread (median absolute deviation)
103K
How far from its usual level
+10.0
Same report last year
135K
History used
2,679 days
the 30 Apr 2025 report24 earlier reportsnormal: 196K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 926K shares sold short in the 15 Apr 2025 report, 5.0× the same report last year.
Same report last year: 184K; its normal report is 187K.
See the evidence
This period
926K (the 15 Apr 2025 report)
Normal report (median of 24 earlier)
187K
Typical spread (median absolute deviation)
89K
How far from its usual level
+5.6
Same report last year
184K
History used
2,664 days
the 15 Apr 2025 report24 earlier reportsnormal: 187K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.2M shares sold short in the 31 Mar 2025 report, 7.2× the same report last year.
Same report last year: 162K; its normal report is 173K.
See the evidence
This period
1.2M (the 31 Mar 2025 report)
Normal report (median of 24 earlier)
173K
Typical spread (median absolute deviation)
80K
How far from its usual level
+8.4
Same report last year
162K
History used
2,649 days
the 31 Mar 2025 report24 earlier reportsnormal: 173K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 851K shares sold short in the 14 Mar 2025 report, 14× the same report last year.
Same report last year: 59K; its normal report is 150K.
See the evidence
This period
851K (the 14 Mar 2025 report)
Normal report (median of 24 earlier)
150K
Typical spread (median absolute deviation)
64K
How far from its usual level
+7.4
Same report last year
59K
History used
2,632 days
the 14 Mar 2025 report24 earlier reportsnormal: 150K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 902K shares sold short in the 28 Feb 2025 report, 8.4× the same report last year.
Same report last year: 107K; its normal report is 136K.
See the evidence
This period
902K (the 28 Feb 2025 report)
Normal report (median of 24 earlier)
136K
Typical spread (median absolute deviation)
55K
How far from its usual level
+9.5
Same report last year
107K
History used
2,618 days
the 28 Feb 2025 report24 earlier reportsnormal: 136K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 7 insiders buy $655K of its shares on the open market within 30 days (7 filings).
Who bought: Arkowitz David, Brenner Martin, Duran Felipe, Sender Gary and 3 more.
See the evidence (7 source records)
Independent buyers
7
Purchase filings (Form 4, code P)
7
Total bought
$655K
Window
15 Dec 2024 to 14 Jan 2025
Arkowitz David (director) bought 18,382 shares of IBIO ($49,999)dated 13 Jan 2025, public 14 Jan 2025
Brenner Martin (See Remarks) bought 9,191 shares of IBIO ($25,000)dated 13 Jan 2025, public 14 Jan 2025
Duran Felipe (Chief Financial Officer) bought 9,191 shares of IBIO ($25,000)dated 13 Jan 2025, public 14 Jan 2025
Sender Gary (director) bought 9,191 shares of IBIO ($25,000)dated 13 Jan 2025, public 14 Jan 2025
Parada Antonio Bernardino Guimaraes (director) bought 183,823 shares of IBIO ($499,999)dated 13 Jan 2025, public 14 Jan 2025
Banjak Marc (Chief Legal Officer) bought 9,191 shares of IBIO ($25,000)dated 13 Jan 2025, public 14 Jan 2025
Clark William D (director) bought 1,838 shares of IBIO ($4,999)dated 13 Jan 2025, public 14 Jan 2025
Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.
Showing the newest 40 of 140 entries; narrow the window or the kind of data to see older ones.
Not listed: 196 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001420720
Ticker
IBIO
Domain
ibioinc.com
Hq location
NY|NEW YORK|10022 (1 unverified)
Lobbying client
ibio
Name
iBio, Inc., iBioPharma, Inc., InB:Biotechnologies, Inc.
Federal lobbying disclosures (LDA)4 records, 30 data points8 Apr 2020 to 30 Sep 2022
SEC Form 13F institutional holdings481 data points30 Jun 2013 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)258 records14 Jan 2016 to 20 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)967 data points30 Jun 2010 to 10 Nov 2026
SEC Form 4 insider transactions34 records, 104 data points27 Jan 2016 to 27 Mar 2026
FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026